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Abstract: Exosomes are naturally occurring nanovesicles that can be tailored to display a 
broad range of drug targets, including G protein-coupled receptors. Such vesicles provide a new 
source of complex membrane proteins that are maintained in their native conformation. Given 
the difﬁ  culties to isolate receptors for drug target validation and discovery, receptor presenta-
tion on exosome emerges as a promising new tool for drug screening. The potential of this 
technology is illustrated here with recombinant exosomes presenting the somatostatin receptor 
2 as an example. The receptor-containing vesicles were identiﬁ  ed as exosomes since they also 
bear Lactadherin, a hallmark of exosome nanovesicles. The amount of somatostatin receptor 
2 on exosomes was similar to the amount of the most abundant known exosome membrane 
proteins. The receptor was functional and similar in size to the form found on cell surface. Fi-
nally, recombinant exosomes were used in several assay formats that exemplify their capacity 
as a new receptor presentation platform for drug discovery. These include the induction and 
detection of antibody as well as screening of antibody repertoires without the need to purify 
membrane proteins.
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Introduction
G protein-coupled receptors (GPCRs) constitute the largest family of receptors in the 
human genome (Pierce et al 2002). A large proportion of drugs currently on the market 
targets members of this family of receptors (Hopkins and Groom 2002; Klabunbe and 
Hessler 2002). Not surprisingly, this pharmacologically important group is the subject 
of continued interest with two thirds of drugs in development involving direct binding 
to GPCRs or interfering with GPCR-coupled pathways (Med Ad. News 2004). GPCRs 
share several common features, including the coupling of their signal transduction via 
G proteins and a structure with seven transmembrane domains (Gether 2000; Jacoby 
et al 2006; Lundstrom 2006). The latter renders this family of receptors difﬁ  cult to 
produce and purify in large quantities (Helenius and Simons 1975; Sarramegna et al 
2003; Lundstrom 2006). Previous drug development focused primarily on a limited 
number of GPCR family members on a gene by gene-based approach as new genes 
were identiﬁ  ed and their product successfully isolated. The growing size and number 
of library of compounds available for drug screening and the recent identiﬁ  cation of 
several hundreds of new GPCR sequences by genome sequencing has recently trans-
formed the ﬁ  eld of GPCR-targeted drug discovery (Pierce et al 2002). A large number of 
these new receptors are orphan receptors for which ligands are still unknown. Reagents 
such as monoclonal antibodies are needed to characterize and validate novel GPCRs 
as potential drug targets. There is also considerable interest in developing technologies 
and tools that facilitate the preparation and isolation of GPCR for high throughput 
screening of small molecule libraries (Lundstrom 2006). Ideally, such technologies 
should enable isolating material without a denaturing step such as solubilization with International Journal of Nanomedicine 2007:2(4) 752
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detergent. They should maintain GPCR in their native con-
formation and environment, ie, in a lipid bilayer structure and 
preferably derived from cells and tissues in which GPCRs 
are potentially pharmacologically relevant. Finally, these 
technologies should yield homogenous preparations and be 
applicable to many members of the GPCR family. In this 
regard, we have recently reported on a technology called 
Exosome Display that enables the presentation of soluble 
proteins, extracellular domains of receptors, as well as full-
length membrane proteins on naturally occurring exosome 
nanovesicles (Delcayre, Estelles, et al 2005). This technology 
is amenable to drug screening studies while alleviating the 
drawbacks of existing approaches used to isolate membrane 
proteins.
Exosome nanovesicles of 50–100 nm are formed in 
intracellular vesicular bodies of most cells and released in 
the extracellular milieu following fusion of the vesicular 
body and plasma membranes (Johnstone 1992; Denzer et al 
2000; Thery et al 2002). Exosome Display relates to two 
modes of protein transfer to exosomes (Delcayre, Estelles 
et al 2005). The ﬁ  rst mode of transfer applies to soluble 
proteins and extracellular domains of receptors. It involves 
the C1C2 domain of Lactadherin which mediates the speciﬁ  c 
targeting of fusion proteins to the exosome compartment. 
The second mode applies to full-length membrane proteins, 
including GPCRs. Unexpectedly, Exosome Display of 
receptors does not require any sequence modiﬁ  cation; how-
ever, the subcellular distribution of unmodiﬁ  ed membrane 
proteins is not restricted to the exosomal vesicles since 
full-length receptors are also found on the plasma mem-
brane. The mechanism of membrane protein trafﬁ  cking to 
exosomes is unclear. We have found that overexpression of 
membrane proteins results in the distribution of a signiﬁ  cant 
number of receptor molecules per exosomes, even if they 
do not occur there naturally (Delcayre, Estelles et al 2005). 
Exosomes, notably dendritic cell-derived exosomes (Dexo-
somes), have drawn considerable interest because of their 
immunological properties (Zitvogel et al 1998; Thery et al 
1999, 2002; Lamparski et al 2002; Vincent-Scheinder et al 
2002; Andre et al 2004). Their studies culminated with the 
evaluation of patient-derived Dexosomes for the treatment 
of cancer (Delcayre, Shu et al 2005). Two Phase I clinical 
trials of autologous Dexosomes therapy for non-small cell 
lung (NSCL) and melanoma cancer patients, respectively, 
were completed that established the feasibility and safety of 
this approach (Morse et al 2005; Escudier et al 2005). As 
new exosome properties and technologies unveil, a growing 
number of possible applications is emerging in the ﬁ  elds of 
vaccine (Delcayre and Le Pecq 2006), autoimmune diseases 
(Abusamra et al 2005; Kim et al 2005; Taylor et al 2006), 
and transplantation (Morelli 2006; Peche et al 2006). Here, 
the potential of Exosome Display as a promising receptor 
presentation platform for GPCR-targeted drug discovery was 
evaluated. The technology was applied to the generation and 
screening of antibodies in various assay formats using the 
somatostatin receptor 2 (SSTR-2) as an example.
Material and methods
Material
All cell lines were purchased from ATCC except D2SC-1 
and Phoenix (E and A) cells that were kindly provided by 
Dr. Riccardo and Dr. Nolan (Stanford University, Palo 
Alto, CA), respectively. Human Embryonic Kidney 293-F 
cells were maintained in 293-SFM II medium (Invitrogen, 
San Diego, CA) supplemented with fetal bovine serum 
(FBS; 2%) except for exosome production where cells 
were transferred to a chemically deﬁ  ned CD293 medium 
(Invitrogen). Mouse A20 and YAC cells were maintained in 
ADCF medium (HyClone, Logan, UT) supplemented with 
FBS (2%). For exosome production, cells were transferred 
to ADCF medium without serum. Mouse D2SC-1 and EL4 
cells were maintained in AIMV (Invitrogen) supplemented 
with FBS (2%). Again, for exosome production, cells 
were transferred to protein free-AIMV medium. Phoenix 
cells were grown in DMEM-high glucose supplemented 
with 10% FBS. Commercially available antibodies were 
purchased from Pharmingen, San Diego (PE-conjugated 
anti-CD19 antibody; PE-conjugated anti-rat Ig antibody; 
Alexa-conjugated Streptavidin), and Roche, Palo Alto (Rat 
anti-HA tag antibody; Horse Radish Peroxidase-conjugated 
anti-HA tag antibody). The polyclonal anti-Lactadherin anti-
body was a gift from Dr. Sebastian Amigorena (Institut Curie, 
Paris, France). Biotinyl Somatostatin-28 was purchased from 
Bachem Bioscience (King of Prussia, PA).
Cloning of SSTR-2 and preparation
of recombinant cell lines
HA-tagged SSTR-2 was prepared using a previously reported 
method (Koller et al 1997). Brieﬂ  y, SSTR-2 cDNA was 
prepared by RT-PCR of human brain RNA (Clonetech, 
Palo Alto, CA) using primers designed for cloning into 
HApC3.1, as previously described (Delcayre, Estelles, 
et al 2005). HA-SSTR-2 insert was then subcloned into the 
retroviral shuttle vector pBABE MN IRES GFP to produce 
recombinant retrovirus as previously reported (Swift et al 
1999). For this, Phoenix cells (2 × 106) were transfected with International Journal of Nanomedicine 2007:2(4) 753
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3 μg pBABE MN-HASSTR2- IRES GFP using Fugene 6 
(Roche, Palo Alto, CA) according to the manufacturer’s 
recommendations. Forty eight hours post-transfection, 
culture supernatants were collected, ﬁ  ltered through 0.45 μm-
ﬁ  lters and used to infect 5 × 105 target cells. Forty eight hours 
post-infection, cells were immunostained using a puriﬁ  ed 
rat anti-HA antibody followed by anti-rat antibody coupled 
to PhycoErythrin (PE). Cells were isolated by ﬂ  uorescent-
activated sorting (FACS) and expanded. Viral particles pro-
duced by Phoenix E cells were used to transduce mouse cell 
lines, while 293-F cells were transduced with viral particles 
obtained from Phoenix A cells.
Exosome preparation
Cells were transferred into protein-free medium as described 
above and exosomes were produced during 5-day cultures. 
Exosomes were prepared as previously described (Lamparski 
et al 2002) with some modiﬁ  cations (Delcayre, Estelles, et al 
2005). Brieﬂ  y, the culture supernatant was cleared from 
cell debris and large vesicles by centrifugation at 2,000 rpm 
for 10 minutes followed by 0.8 and 0.2 μm ﬁ  ltrations. 
Supernatant concentration and buffer-exchange to PBS was 
performed by ultraﬁ  ltration/diaﬁ  ltration using a ﬁ  ber car-
tridge with a 500 kD cut-off. The concentrated fraction was 
subjected to ultracentrifugation on a 30%-sucrose cushion 
in PBS/D2O and exosomes were recovered by collecting the 
sucrose-containing layer. The exosome fraction was further 
concentrated and diaﬁ  ltered to yield a 500X-concentrated 
solution of puriﬁ  ed exosomes. Exosomes were aliquoted 
and stored at –80 °C until use. Protein content of puriﬁ  ed 
exosomes was determined using a Bradford assay (Pierce, 
Rockford, IL). Exosomes prepared following this method 
appear as a homogeneous population of vesicles 50–100 nm in 
diameter when evaluated by electron microscopy (Lamparski 
et al 2002).
Cross-capture and adsorption ELISA
ELISA was performed as previously described (Lamparski 
et al 2002) with some modiﬁ  cations (Delcayre, Estelles, 
et al 2005). Brieﬂ  y, for adsorption ELISA, exosomes were 
directly coated to the wells of microtitration plates placed 
overnight at 37 °C. The plate was washed and blocked in 
PBS/0.05% Tween 20 and incubated for one hour at room 
temperature with anti-HA antibody coupled to HRP. Bound 
antibodies were detected using an ECL Western blot detec-
tion reagent (Amersham Bioscience, Piscataway, NJ, USA) 
and measuring light emission on a Wallac Microbeta 1450 
Trilux plate reader (PerkinElmer Life Sciences Inc., Boston, 
MA, USA). For capture ELISA, the wells of microtitration 
plates were coated with monoclonal anti-CD81 or anti-
HA antibodies (2 μg/mL). Following PBS washing and 
PBS/0.05% Tween 20 blocking steps, serial dilutions of 
exosomes were added to each well and incubated overnight 
at room temperature. After washing, bound exosomes were 
detected with either biotinylated anti-CD81 antibody fol-
lowed with streptavidin-HRP conjugate, anti-HA antibody 
conjugated to HRP, or polyclonal anti-Lactadherin antibody 
followed with anti-rabbit antibodies coupled to HRP (Jackson 
ImmunoResearch Laboratories, West Grove, PA). ELISA 
measurement was performed as above using ECL Western 
blot detection reagent.
Western blot analysis of exosomes
and membrane fractions
Exosomes were prepared as described above. Crude 
plasma membranes were prepared by homogenizing cells 
resuspended in 10 mM Tris/HCl pH7.6, 2mM MgCl2, and 
a cocktail of protease inhibitors (Roche, Palo Alto, CA), 
using a glass homogenizer. Homogenized cells were spun 
at 500 g for 5 minutes at 4 °C and the supernatant was 
retained. The procedure was repeated with the pellet and 
both supernatants were pooled and spun at 10,000 g for 30 
minutes. The pellet was resuspended in 50 mM Tris/HCl, 
pH7.6, 7mM MgCl2, protease inhibitors, and 2mg/ml DβM 
-n-Dodecyl-β-maltoside. The resulting solution was retained 
as the plasma membrane fraction. For Western blot analysis, 
ﬁ  fty μg of membrane fraction and 5 μg of puriﬁ  ed exosomes 
were diluted 1:1 in 2X SDS-PAGE sample buffer and heat-
denatured for 5 min. Following electrophoresis, samples were 
transferred to PVDF membrane that were then blocked by 
incubation into PBS/0.05% Tween 20/6% non-fat milk for 1 
hour at RT. The presence of an HA tag on the membrane was 
evaluated by probing with an anti-HA antibody conjugated to 
HRP. Bound antibodies were then detected using CN/DAB 
chromogenic substrate (Pierce, Rockford, IL).
SSTR-2 ligand binding assay
SSTR-2/YAC cells were washed with PBS and resuspended 
in FACS staining buffer (PBS-4% FBS) containing different 
amounts of Biotinyl-Somatostatin-28 (Bachem Bioscience, 
King of Prussia, PA). Following a 1-hour incubation at 4 °C, 
excess ligand was removed by washing cells in staining 
buffer. Bound ligand was detected by ﬂ  ow cytometry after 
incubation of the cells with Streptavidin coupled to PE. For 
competition assay, incremental amounts of exosomes were 
added to cells during incubation with 7.5 nM SSTR-2 ligand. International Journal of Nanomedicine 2007:2(4) 754
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The ligand concentration was determined empirically based 
on the concentration range that yielded binding within the 
linear trendline of the assay.
Induction and analysis of anti-SSTR-2 
antibody response
Mice were immunized with recombinant SSTR-2/exosomes 
by subcutaneous injections in both footpads. Mice received 
5 μg of SSTR-2/YAC exosomes in PBS in each footpad and 
immunizations were performed at 1-week intervals for the 
ﬁ  rst two injections and at two week intervals thereafter. 
Induction of anti-SSTR-2 antibodies was evaluated by 
adsorption ELISA as described above using serum from 
blood samples collected 1 week following the second in-
jection. The detection of anti-SSTR-2 antibody-producing 
cells was performed by ﬂ  ow cytometry using popliteal 
lymph nodes and spleen cells of mice one, two, or ﬁ  ve 
days following the last immunization. For this analysis, 
single cell suspensions (5 × 105 cells) were preincubated 
for 15 min. on ice with 25 μg of parental 293 exosomes. 
Biotinylated recombinant SSTR-2/293 exosomes (1 μg) 
prepared as previously described (10) were then added to 
the samples and incubation continued for 45 min. Cells 
bearing exosomes and CD19+-cells were detected by stain-
ing with Streptavidin-Alexa and anti-CD19-PE antibody 
conjugates, respectively, followed by FACS analysis.
Results
Recombinant cells release exosomes 
containing the somatostatin receptor, 
SSTR-2
The expression of GPCRs on vesicles released in the 
supernatant of recombinant cells was previously exam-
ined by cross-capture ELISA with anti CD81 and anti-HA 
antibodies (Delcayre, Estelles, et al 2005). To fully identify 
these vesicles as exosomes, assays were repeated using anti-
bodies against Lactadherin, a hallmark protein of exosomes 
(Delcayre and Le Pecq 2006), and SSTR-2 as a model for 
GPCR. Recombinant SSTR-2/293 cells were cultured in pro-
tein-free medium and exosomes released in the extracellular 
medium were puriﬁ  ed as described in Material and Methods. 
The display of recombinant SSTR-2 on 293 exosomes was 
demonstrated in cross-capture ELISA measuring the physi-
cal association between CD81, the HA-tag of SSTR-2 and 
Lactadherin. As shown in Figure 1A, speciﬁ  c binding of anti-
HA antibody to vesicles captured with an anti-CD81 antibody 
was detected when using exosomes produced by recombinant 
SSTR-2 cells. No signal was detected when using the same 
antibody combination with exosomes from parental cells. 
In contrast, identical signals were obtained when detecting 
CD81 on parental and recombinant exosomes supporting 
that exosomes from both recombinant and parental cells 
contained similar amounts of CD81 molecules (Figure 1B). 
The identiﬁ  cation of vesicles as true exosomes was then 
established in cross-capture assays using an anti-lactadherin 
antibody for detection. Indeed, unlike CD81 that can be found 
in different subcellular compartments, Lactadherin is found 
exclusively on exosomes but not on the surface of the cells 
used in this assay (Delcayre, Estelles, et al 2005). As shown 
in Figure 1C, similar amounts of Lactadherin were detected 
on both parental and recombinant exosomes captured via their 
CD81. In contrast, speciﬁ  c binding of the anti-Lactadherin 
antibody to vesicles captured with the anti-HA antibody was 
detected when using exosomes produced by recombinant 
SSTR-2 cells only (Figure 1D). Background signal was 
detected when using the same antibody combination with 
exosomes from parental cells. Overall, this data indicate 
that recombinant SSTR-2 is released in a particulate form 
in association with other membrane proteins like CD81. The 
CD81 and GPCR-containing vesicles are exosomes since 
they also contain Lactadherin, which is a speciﬁ  c marker of 
exosomes produced by these cells.
To verify that release of GPCR-containing exosomes by 
recombinant 293 cells is a general phenomenon, recombinant 
cell lines of various types were generated. For each cell line 
tested, infection was performed with the same retrovirus 
and all cell lines were placed in appropriate protein-free 
media during the exosome production phase. As shown in 
Figure 2A, all recombinant cell lines tested released exo-
somes containing HA-tagged SSTR-2. Exosomes from the 
recombinant mouse cell line A20, EL4 and YAC displayed 
similar amounts of SSTR-2 per microgram of vesicles as 
recombinant 293 cell-derived exosomes. Lower amounts 
were detected in D2SC-1-derived exosomes. No HA-tagged 
component was revealed in exosomes from parental cell lines. 
The number of GPCR per exosome was estimated by West-
ern blot analysis using a HA multitag quantization marker 
(Figure 2B). According to the manufacturer’s description 
and the exosome amounts used for the western blot, anti-HA 
tag antibody detected approximately 1 to 3 ng of HA tag per 
μg of exosomes. Based on the molecular weight of SSTR-2 
and previous quantization of Dexosome markers, it can be 
estimated that there are 10 to 30 molecules of SSTR-2 per 
exosome. This estimate of multiple copies of SSTR2 per exo-
somes was corroborated by a different quantization method International Journal of Nanomedicine 2007:2(4) 755
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using exosome-coated beads analyzed by FACS. This method 
measures the amount of markers on exosome-coated beads 
using a calibration bead kit for marker-speciﬁ  c antibodies 
(Quantum Simply Cellular kit; Bangs Laboratories, Fishers, 
IN). The number of exosomes per bead is estimated as previ-
ously described using an occupancy prediction of 50% (Feder 
1980). Such occupancy rate was corroborated by electronic 
microscopy analysis of exosome-coated beads (Clayton et al 
2001). This approach revealed values of 5 to 10 copies of 
SSTR-2 per exosome. As a comparison, the most abundant 
marker detected on Dexosomes is MHC-Class II which 
represents approximately 3% to 6% of the exosome surface 
proteins. Quantization by ﬂ  ow cytometry of exosome-coated 
beads revealed values of 30–60 molecules of MHC class II 
per Dexosome (Roulon et al in preparation). Hence, the num-
ber of SSTR-2 molecules on exosomes is signiﬁ  cant and near 
that of the most abundant known Dexosome markers.
Recombinant exosomes contain the 
mature and functional form of SSTR-2
To further characterize SSTR-2 on exosomes, the bio-
chemical properties of SSTR-2 found on exosomes and 
plasma membranes from different cell lines were analyzed 
by electrophoresis in reducing and denaturing conditions. 
As shown in Figure 3A, the electrophoretic migration of 
SSTR-2 from recombinant A20 and YAC cells was similar, 
whereas a larger size protein was detected in exosomes from 
recombinant EL4 cells. These apparent molecular weight 
variations reﬂ  ect more likely differences in post-translational 
modiﬁ  cation or glycosylation of SSTR-2 in the recombinant 
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Figure 1 Cross-capture ELISA detecting SSTR-2 on exosomes. The wells of microtitration plates were coated with either monoclonal anti-CD81 antibody (panel A, B and 
C) or monoclonal anti-HA antibody (panel D). Exosomes from 293 cells (empty bars) and from recombinant SSTR-2/293 cells (black bars) were added to the wells and 
antigens on captured exosomes were detected with (A) Monoclonal anti-HA antibody (HA Ab) and control isotype-matching antibody (Ctr Ab), (B) monoclonal anti-CD81 
antibody (CD81 Ab) and control isotype-matching antibody (Ctr Ab) and (C) and (D) polyclonal anti-Lactadherin antibody (LTDN) and control pre-immune serum (Ctr 
Ser.) Bound antibodies were detected with species-speciﬁ  c antibodies conjugated to HRP. Cross-capture of serial dilution of exosomes in duplicate was performed for each 
antibody pairs. Data represent the slope of the linear trendline obtained for each exosome serial dilutions used.
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Figure 2 Detection of SSTR-2 on recombinant exosomes from diverse origins. (A) The wells of microtitration plates were coated with incrementing amounts of exo-
somes derived from recombinant A20 (ﬁ  lled triangles), D2SC-1 (ﬁ  lled diamonds), YAC (ﬁ  lled circles), EL4 (open triangles) and 293 (ﬁ  lled squares) cells expressing SSTR-2. 
A monoclonal anti-HA antibody conjugated to HRP was used to detect SSTR-2. Each data point represents the mean of duplicates. Background counts below 1.E4 were 
detected when wells were coated with exosomes from parental cell lines (data not shown). (B) Western blot analysis of HA multitag markers (4, 2, 1 and 0.5 ng of p30) and 
recombinant SSTR-2/YAC exosomes (5, 2.5, 1.25, 0.625 μg exosomes). HA-containing proteins were detected with a monoclonal anti-HA antibody conjugated to HRP and 
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cell lines tested. Remarkably, the same electrophoretic proﬁ  le 
was detected when analyzing plasma membrane fractions. 
Figure 3B shows that like for exosomes, SSTR-2 in plasma 
membrane from recombinant EL4 was larger in size than 
SSTR-2 on plasma membrane of both recombinant A20 and 
YAC cells. However, for each cell line, the same protein size 
was detected in both subcellular compartments. Similar data 
was observed in 293 cells (data not shown). These ﬁ  ndings 
support that regardless of the glycosylation state provided 
by the cells used to express recombinant SSTR-2, exosomes 
more likely contain the mature form of the GPCR that is also 
found at the cell surface. It should be noted that the size of 
proteins detected by Western blot and shown in Figure 3 
is 2-fold higher than the expected size of SSTR-2. It is 
therefore likely that dimeric forms of SSTR-2 were detected 
in this experiment.
We then evaluated whether SSTR-2 on exosomes can 
bind its native ligand, somatostatin. An assay was performed 
to measure the binding of biotynilated somatostatin-28 
(Biot-SST) to recombinant YAC cells expressing SSTR-2. 
Bound Biot-SST was detected by FACS analysis of YAC 
cells stained with Streptavidin-Phycoerithrein conjugate. The 
concentration of Biot-SST for which linear dose-dependent 
binding was reached was determined empirically and the 
assay was repeated in the presence of recombinant exosomes 
expressing SSTR-2. As shown in Figure 4, Biot-SST at 
7.5 nM resulted in a speciﬁ  c staining of recombinant YAC 
cells with an MFI of ∼50. Decreased staining was observed 
when 100 micrograms of recombinant exosomes expressing 
SSTR-2 was added to the sample. Binding of Biot-SST 
to YAC cells was at background level in the presence of 
300 micrograms of exosomes. No signiﬁ  cant decrease of Biot-
SST binding was detected when using parental exosomes (data 
not shown). These data demonstrate that SSTR-2 on exosomes 
can compete with SSTR-2 at the cell surface for its binding to 
Somatostatin. Hence, mature SSTR-2 on exosomes is also in 
a native conformation enabling ligand binding.
Recombinant exosomes are suitable 
immunogens for the induction of
anti-GPCR antibodies
The potency of recombinant exosomes as a novel immu-
nogen platform for the induction of anti-GPCR antibodies 
was evaluated in mice. In order to minimize anti-exosome 
responses, the experiment was performed in a syngeneic 
environment where exosome-producing cell line and animals 
have the same genetic haplotype. To fully appreciate the 
potency of the approach, mice were immunized with low 
amounts of SSTR-2. No adjuvant other than the exosome 
vesicle itself was added and antibody induction was evalu-
ated after two immunizations only. Mice were treated twice 
at one week intervals with 10 μg of SSTR-2/YAC exosomes. 
Based on the estimated number of SSTR-2 molecules per 
exosome, approximately 100 to 200 ng of SSTR-2 was 
injected at each treatment in the mice receiving recombinant 
exosomes. Antibody induction was detected using an ELISA 
in which exosomes were directly adsorbed to the wells of a 
microtitration plate. To avoid the detection of non-speciﬁ  c 
anti-YAC exosome antibodies in the serum of immunized 
mice, the ELISA was performed using recombinant and 
parental exosomes from a different cell type. As shown in 
Figure 5, a speciﬁ  c signal was detected when the serum of 
mice immunized with recombinant YAC exosomes were 
applied to the wells coated with SSTR-2/293 exosomes but 
not parental 293 exosomes. Although the detection of anti-
SSTR-2 antibody induction required low serum dilutions, a 
speciﬁ  c response could be detected in all three mice tested. 
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Figure 3 SDS-PAGE analysis of recombinant SSTR-2 expressed by various cell lines. SSTR-2 in exosomes (panel A) and plasma membranes (panel B) were analyzed by 
SDS-PAGE followed by Western blot analysis using a monoclonal anti-HA antibody conjugated to HRP and chromogenic substrate. Material loaded on the gel was derived 
from parental and recombinant YAC cells (lane 1 and 2), EL4 cells (lane 3 and 4) and A20 cells (lane 5 and 6).International Journal of Nanomedicine 2007:2(4) 757
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The modest but speciﬁ  c antibody titer detected is more likely 
due to the immunization regimen used where antibody induc-
tion was evaluated upon exposure to low amounts of SSTR-2. 
Remarkably, detectable antibody induction was achieved 
using only 1%–2% of a standard exosome preparation from 
the supernatant of a 1-Liter culture.
Recombinant exosomes are suitable 
for the screening of GPCR-binding 
compounds
The possibility of using recombinant exosomes for the 
screening of GPCR-binding compounds was ﬁ  rst illustrated 
above using an ELISA-based screening assay. The versatility 
of exosomes as a source of material for screening reper-
toires of GPCR-binding entities was further demonstrated 
in a different assay format identifying cells that express 
antibodies reacting with GPCRs. For this approach, the 
immunization regimen described above was extended with 
several additional boosts. Local lymph nodes were isolated on 
the day following the last injection. Single cell suspensions 
were prepared and incubated with biotinylated 293 exosomes 
containing SSTR-2 in the presence of an excess of parental 
293 exosomes to saturate putative non-speciﬁ  c interactions. 
A PE-conjugated anti-CD19 antibody was also added to the 
cell suspension to identify B-cells and cells reacting with 
biotinylated exosomes were detected with Streptavidin-Alexa 
conjugates. As shown in Figure 6, 0.56% of CD19-positive 
cells from lymph nodes of immunized mice reacted with 
SSTR2-containing exosomes whereas CD19-negative cells 
from the same organ did not. In contrast, background level 
(0.09%) of double positive cells was detected when the assay 
was performed using lymph nodes of naïve mice. There was 
also no signiﬁ  cant difference between cell populations from 
naïve and immunized mice when biotinylated parental 293 
exosomes were used in the assay (data not shown). Hence, the 
speciﬁ  c staining of CD19-positive cells reﬂ  ects more likely 
the interaction of SSTR-2 with antibodies at the surface of 
cells induced upon immunization. These data demonstrate 
that recombinant exosomes could be used to identify and 
isolate antigen-speciﬁ  c antibody-producing cells.
Discussion
Exosomes are naturally occurring nanovesicles with a broad 
spectrum of biological activities in line with their protein 
compositions. Although the antigen presentation and immune 
modulation properties of these vesicles have attracted a lot 
of interest for their use in cancer therapy (Thery et al 2002; 
Delcayre, Shu et al 2005), a growing ﬁ  eld of biotechnology 
applications is emerging as new discoveries unfold (Delcayre 
and Le Pecq 2006). Notably, Exosome Display is a novel 
technology enabling to manipulate the protein content of 
exosomes that opens many possibilities. These include 
applications in the ﬁ  eld of drug target validation and screen-
ing of libraries of compounds binding to drug targets. As an 
example, we used SSTR-2 to characterize the biochemical 
properties of the receptor released with exosomes and show 
that the latter can be utilized in various assay formats for 
drug discovery.
The presence of particle-bound SSTR-2 in the culture 
supernatant of recombinant cells was established as previ-
ously described for CXCR4 and CCR7 (Delcayre, Estelles, 
et al 2005), by cross capture ELISA linking SSTR-2 to 
CD81-containing vesicles. The vesicles were further iden-
tiﬁ  ed here as exosomes in cross-capture ELISA linking 
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Figure 5 Detection of anti-SSTR-2 antibody in serum of mice immunized with 
SSTR-2/YAC exosomes. Serum of three immunized mice was added to the wells 
of microtitration plate coated with exosomes from parental (empty bars) or 
recombinant SSTR-2 293 cells. Bound antibodies were detected with an anti-mouse 
IgG antibody conjugated to HRP and chemiluminescent substrate. Data represent 
the mean of duplicate wells. Background signal obtained with serum of non-
immunized mice was subtracted.
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Figure 4 Binding of Biotinylated SST-28 to recombinant SSTR-2/YAC cells. SSTR-2/
YAC cells were incubated with (ﬁ  lled diamonds) or without (empty diamonds) bio-
tinylated SST-28 in the presence of incremental amounts of SSTR-2/YAC exosomes. 
Cells stained with Streptavidin-PE were analyzed by FACS. The assay was repeated 
successfully twice and data of one representative experiment are shown.International Journal of Nanomedicine 2007:2(4) 758
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SSTR-2 to Lactadherin, a hallmark of exosomes. Indeed, 
Lactadherin produced by cells other than mammary cells 
has been shown to be released in association with exosomes 
(Oshima et al 2002; Miyasaka et al 2004; Veron et al 2005; 
Delcayre and Le Pecq 2006). Moreover, Lactadherin is not 
found on the surface of healthy cells while many membrane 
proteins found on the cell surface are not present on Lacta-
dherin-containing vesicles (Delcayre and Le Pecq 2006). 
This further distinguishes Lactadherin-containing vesicles 
as exosomes which originate in an intracellular compartment 
from other vesicles budding from the cell surface which could 
also contain GPCRs.
Exosome Display of SSTR-2 was achieved on exosomes 
derived from various cell types and resulted in the presenta-
tion of 5–30 molecules per vesicles. This ﬁ  gure is remarkably 
high and is similar to the number previously established for 
the most abundant proteins present in dendritic cell-derived 
exosomes. Hence, the detection of GPCRs in exosomes is 
speciﬁ  c and unlikely due to contamination by other vesicles. 
The latter generally accounts for a fraction of the prepara-
tion and component quantity much below 1 molecule per 
vesicle. So far, the speciﬁ  c detection of signiﬁ  cant amounts 
of recombinant GPCRs on exosomes has been successfully 
attempted with ﬁ  ve GPCR models, including SSTR-2, CCR7, 
CXCR4, CD97 and CCR5. Surprisingly, trafﬁ  cking of these 
receptors to the exosome compartment did not require any 
sequence modiﬁ  cation. This is in contrast with Exosome 
Display of soluble antigen and extracellular domains of 
membrane proteins which is achieved via speciﬁ  c targeting 
of chimeric proteins fused to an exosome localization domain 
(Delcayre, Estelles et al 2005). The mechanism leading to 
the GPCR distribution in exosomes is unknown. It is non-
exclusive in that the receptors were also found in the plasma 
membrane. In addition, the level of GPCR expression in the 
vesicles varied with the model used and was proportional to 
the overall level of GPCR expression in recombinant cells 
(data not shown).
An important feature of SSTR-2 on exosomes is its 
similarity with the receptor form found on the cell surface. As 
expected, we detected different forms of SSTR-2 produced 
by various cell lines that most likely result from cell-speciﬁ  c 
post-translational modiﬁ  cation. In the cell lines tested here, 
the form of SSTR-2 found on exosomes mirrored that found 
on the surface of the matching exosome-producing cell line. 
This indicates that the fully post-translationally modiﬁ  ed 
form of the receptor trafﬁ  cs to the exosome compartment 
for release. Finally, we showed that SSTR-2 on exosomes 
is functional in its ability to bind to its native ligands. 
This was demonstrated in competition experiment where 
SSTR-2-containing exosomes could block binding of bioti-
nylated SST-28 to its receptor on SSTR-2-expressing cells. 
Further experiments will be required to determine whether the 
afﬁ  nity of SSTR-2 ligand for its receptor is similar when the 
latter is presented on exosomes or on cell surfaces. However, 
this data indicates that SSTR-2 on exosomes is most likely 
properly folded and oriented in the lipid bilayer to allow for 
binding to ligands.
Recombinant exosomes represent an ideal source of 
material where receptors are in their native conformation. 
A robust and reliable procedure has been established to 
reproducibly isolate and characterize exosomes (Le Pecq 
2005; Patel et al 2005). The same procedure can be per-
formed regardless of the nature of the recombinant receptor 
expressed on exosomes and of the cell type used to produce 
exosomes. The puriﬁ  cation process used is devoid of any 
denaturing steps and the receptors are maintained in their 
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Figure 6 Detection of anti-SSTR-2 antibody producing B-cells in Lymph nodes of mice immunized with SSTR-2/YAC exosomes. Lymph node cells from naïve mice (A) and 
mice immunized with SSTR-2/YAC exosomes (B) were incubated with biotinylated SSTR-2/293 exosomes and a 25X excess of parental 293 exosomes. Cells were then 
stained with Streptavidin-Alexa and anti-CD19-PE antibody conjugates and analyzed by FACS. Numbers in the upper right quadrants indicate the percent of Alexa/PE double 
positive cells. The assay was repeated successfully multiple times and data of one representative experiment are shown.International Journal of Nanomedicine 2007:2(4) 759
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native conformation throughout. The resulting material is 
homogenous as compared to membrane preparation. Indeed, 
the latter may contain large amounts of endogenous GPCRs 
which could temper with assays. As for membrane prepara-
tion, an added advantage of preparing recombinant exosomes 
as a source of GPCR material is that it provides the ﬂ  exibility 
to isolate GPCRs produced by relevant cells, ie, where the 
receptor occurs naturally. In contrast, the preparation of 
recombinant GPCRs in large amount requires using spe-
ciﬁ  c cell expression systems with unique post-translational 
modiﬁ  cation pathways. The use of such heterologous systems 
may therefore result in the production of a different form of 
the receptor than the one desired for drug discovery studies 
(Lundstrom 2005). Also, GPCRs on exosomes are physically 
linked to a particle which can be labeled via diverse standard 
methods targeting speciﬁ  c proteins or lipids. Hence, easy 
detection of particles can be achieved without modifying 
the GPCR itself, which alleviates the risk of encroaching 
on receptor properties.
The potential of recombinant exosomes as a novel 
GPCR platform for drug discoveries was illustrated with 
the induction of anti-SSTR-2 antibodies and screening of 
anti-SSTR-2 antibody repertoire using SSTR-2 exosomes 
as sole source of GPCRs. The induction of anti-SSTR-2 
antibodies in animals was detected following two injections 
only. The immunogen used comprised recombinant exo-
somes derived from syngeneic mouse cells and resuspended 
in PBS with no added adjuvant. Based on the estimated 
number of SSTR-2 molecules per vesicle, the immunogen 
contained approximately 100–200 ng of SSTR-2 at each 
treatment. Although additional boosts and higher amounts 
of immunogen would most likely have resulted in increased 
antibody titers, the conditions used were sufficient to 
induce a response detectable by ELISA using recombinant 
exosomes as antigen. This data confirm that exosomes 
exhibit potent adjuvant activity that renders antigens highly 
immunogenic. They also support that anti-GPCR antibody 
induction and detection can be performed without the need 
to purify receptors. Standard ELISA for antibody detection 
were carried out using ∼ 250 ng of recombinant exosomes 
per well of a 96-well microtitration plate. A 1-Liter culture 
supernatant which generally yields ∼1 to 2 mg of exosomes 
could be used to coat up to 8000 wells. Hence, this approach 
is realistically scalable to also provide the material required to 
screen hybridoma supernatants for the isolation of monoclo-
nal antibodies. The ﬂ  exibility of the exosome-based GPCR 
tool to adapt to various formats was further established in 
soluble phase assay using biochemically labeled exosomes 
and a library of antibody-expressing cells. In this assay, the 
library of antibody repertoire consisted of a suspension of 
cells from lymph nodes of animals immunized with SSTR-2 
exosomes. We showed that CD-19+ cells could be stained 
in an antigen-speciﬁ  c manner. This staining is more likely 
due to an antibody-antigen interaction and therefore enabled 
the identiﬁ  cation of anti-SSTR-2 antibody-producing cells. 
Combined to cell sorting, this approach may enable the 
isolation of antigen-speciﬁ  c antibody producing cells from 
a repertoire library. The detection of anti-SSTR-2 antibody 
producing cells was dependent of the time at which organs 
were collected after the last immunization. Indeed, antigen-
speciﬁ  c staining was maximal at day 1 and lost at day 5 
post immunization. The presence of anti-SSTR-2 antibody 
producing cells was also detected in spleens of immunized 
animals; however, optimal detection occurred at day-5 
post-immunization (data not shown). Further studies will be 
required to determine the precise subtype of B-cells identiﬁ  ed 
with this approach. Regardless, our ﬁ  ndings demonstrate 
that exosome-based GPCR tools are readily suitable for the 
generation of antibodies and screening of antibody repertoires 
without the need to purify receptors. This is notably of vital 
importance for the validation of orphan receptors. More-
over, screening assays can easily be adapted to repertoires 
of different origins (natural, recombinant, or synthetic) and 
compositions (antibodies or small molecules).
Overall, exosomes containing GPCRs as source and form 
of receptors compares favorably to puriﬁ  ed proteins or mem-
brane preparations. In addition to the assay format reported 
here, the different solid support platforms recently described 
for GPCR drug screening such as protein microarrays (Fang 
et al 2002) and parmagnetic proteoliposomes (Mirzabekov 
et al 2000) could also be adapted to utilize recombinant exo-
somes as source of GPCRs instead of membrane preparations 
or puriﬁ  ed receptors. Given the size of exosomes, it can be 
estimated that 16  10–3 fmol of SSTR-2 can be deposited in 
a protein array well of 100 μm when using exosomes bearing 
ten SSTR-2 molecules per vesicles (100 nm diameter vesicle, 
10 SSTR-2 per exosomes and 50% occupancy). This quantity 
is similar to previous estimates when using membrane prepa-
rations (Hong et al 2006). Hence the exosome-based GPCR 
platform provides an enriched source of GPCR maintained 
in their native conformation that should facilitate GPCR drug 
discovery and warrant further evaluation in this ﬁ  eld.
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